P1671Impact of chronic kidney disease on mitral valve repair with the mitraclip system: one-year outcomes frome the GRASP registry stratified by left ventricular dysfunction

Abstract

Background: Chronic kidney disease (CKD) is common in patients with mitral regurgitation (MR) referred for therapy, often being associated with heart failure (HF) and poor prognosis. Purpose(s): The aim of this prospective, observational study was to evaluate the impact of baseline CKD on one-year outcomes of MitraClip therapy in high surgical risk patients with moderate-to-severe or severe MR presenting with HF and reduced ejection fraction (HFrEF) or HF and mid-range ejection fraction (HFmrEF). Method(s): Patients enrolled in the prospective Getting Reduction of Mitral Insufficiency by Percutaneous Clip Implantation (GRASP) with left ventricular (LV) EF <50% and functional MR eligible at one-year follow-up (FU) were included. The primary efficacy endpoint was the composite of death, surgery for mitral valve dysfunction and grade 3/4 + MR at one-year FU. Secondary endpoints were the components of the primary endpoint, re-hospitalization rates and functional NYHA class. Also echocardiographic parameters were assessed. Result(s): A total of 250 patients were included: 202 with HFrEF and 48 with HFmrEF. Baseline CKD occurred in 62.8% of patients with HFrEF and in 56.2% of patients with HFmrEF. Post-procedural residual MR